Table 2.
Summary of action of Rhus Toxicodendron.
| Sr. No | Author | Rhus Tox activity | Potency | Methodology | Conclusion |
|---|---|---|---|---|---|
| 1. | White K (1994) | Recurrent cutaneous HSV-1 clinical trial | Different potencies | Clinical trial | 50% patients were prescribed Rhus Toxicodendron |
| 2. | A L dos Santos et al. (2007) | Carrageenan-induced paw oedema in rats in vivo | 6C, 12C, 30C & 200C | Writhing test in mice, Stress induced gastric lesions | Influence inflammatory processes- histamine, prostaglandins & inflammatory mediators |
| 3. | Allahverdiyev A et al. (2013) | 42 patients- Skin lesions caused by RT ingestion | – | Oral or parenteral contact | Pathophysiology and symptoms justify use of RT against herpes |
| 4. | Huh, Yun Hyun et al. (2013) | Primary cultured mouse chondrocytes in vitro | 4X, 30X, 30C and 200C | Quantitative (real-time) RTPCR or qRTPCR and immunoblot tests. | Increased cox2 mRNA expression, inhibited the expression of type 2 collagen. |
| 5. | Lee, Kyung Jin et al. (2016) | Mc3t3e1 mouse cells in vitro | Different potencies | (RT-PCR) and immunoblotting | Increased PGE2 release with higher levels of COX2 expression |